NNC0519-0130 vs ribupatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Obesitypeptide
Partial signal

NCT06326060 · Phase 2 · completed

The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.

No aligned efficacy figure on record for this race.

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Obesitypeptide
Reliable signal

NCT06396429 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06974851 (registry estimate)

Reported efficacy

Percentage change from baseline in weight after 48 weeks of treatment (Baseline, Week 48); Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment (Week 48): Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss (met)

Result source: NCT06396429

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNC0519-0130ribupatide
Body weight, % change—Not reported—Not posted · NCT06396429
Weight loss of 5% or more—Not reported—Not posted · NCT06396429
Weight loss of 10% or more—Not reported—Not posted · NCT06396429
Waist circumference, change (cm)—Not reported—Not posted · NCT06396429

Body weight, % change

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06396429

Weight loss of 5% or more

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06396429

Weight loss of 10% or more

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06396429

Waist circumference, change (cm)

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06396429
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNC0519-0130: no structured comparison results are available for Obesity.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ribupatide

Weight 17.7% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06396429 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 88%
responder rate · % of participants
No placebo or comparator arm
NCT06396429 · Phase 3 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Type 2 Diabetespeptide
Weak signal

NCT05363774 · Phase 1 · completed

This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06649344 · Phase 3 · completed

This phase 3 trial randomly assigned 884 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to once-weekly ribupatide 4 mg, ribupatide 2 mg or semaglutide 1 mg, with open-label treatment. The primary measure was HbA1c change at week 36, tested for non-inferiority against semaglutide. The company reports that both doses were non-inferior (HbA1c -2.78% and -2.34% against -2.29%) and that 4 mg was statistically superior, so the result is met. The margin and confidence intervals were not published, and the figures come from the company's own release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07060456 (registry estimate)

Reported efficacy

Change in HbA1c (from baseline to 36 weeks treatment): Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo (met)

Result source: NCT06650007

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNC0519-0130ribupatide
HbA1c, change—Not reported—Not posted · NCT06650007
Body weight, change (kg)—Not reported—Not posted · NCT06650007
HbA1c below 7%—Not reported—Not posted · NCT06650007
Fasting plasma glucose, change—Not reported—Not posted · NCT06650007
3-point MACE (% with event)—Not reported—Not posted · NCT06650007

HbA1c, change

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06650007

Body weight, change (kg)

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06650007

HbA1c below 7%

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06650007

Fasting plasma glucose, change

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06650007

3-point MACE (% with event)

NNC0519-0130
—Not reported
ribupatide
—Not posted · NCT06650007
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ribupatide
Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met. NCT06649344 · Phase 3 · design grade: moderate · publication or press release
Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo NCT06650007 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0519-0130's landscape · ribupatide's landscape